Uncategorized

J&J glows with $1B buyout of Firefly and its degrader platform tech

Published

on

The acquisition gives Johnson & Johnson access to Firefly Bio’s next-gen platform designed to create degrader antibody conjugates that can crack the tricky KRAS cancer target.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version